Drugs · Entity Annotation Prototype (beta)

3articles mentioning drugs

3drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Vusolimogene oderparepvec ×

Vusolimogene oderparepvec

This drug is selected. Its supporting articles are shown below.

Vusolimogene oderparepvec3

Articles mentioning Vusolimogene oderparepvec

3 articles · page 1 of 1

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

jitc · abstract · 2026-03-03 · 1 matching annotations

88.5%

vusolimogene oderparepvec RP1 tumor

…s (splenocytes) were cultured separately, or in co-culture with vusolimogene oderparepvec, an oncolytic herpes simplex virus expressing the fusogenic gib…

600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma

jitc · abstract · 2025-11-04 · 1 matching annotations

84.4%

nivolumab nivo RP1 nivo-related

…notherapy. The IGNYTE trial showed that RP1 in combination with nivolumab (nivo) demonstrated clinically meaningful, durable responses (o…

611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy: a subgroup analysis of patients with anti-PD-1-failed BRAF-mutant melanoma from the IGNYTE clinical trial

jitc · abstract · 2025-11-04 · 1 matching annotations

89.9%

nivolumab RP1 Vusolimogene oderparepvec BRAFi melanoma anti-PD-1 therapy

…vec (RP1; an HSV-1-based oncolytic immunotherapy) combined with nivolumab demonstrated clinically meaningful, durable antitumor activity …